<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224428</url>
  </required_header>
  <id_info>
    <org_study_id>FEXT20</org_study_id>
    <nct_id>NCT04224428</nct_id>
  </id_info>
  <brief_title>Role of Fexofenadine in Diabetic Kidney Disease</brief_title>
  <official_title>Role of Fexofenadine in Reducing Albuminurea in Patients With Diabetic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  This study will that will be conducted on 60 outpatients previously diagnosed with type&#xD;
           2 diabetes mellitus.&#xD;
&#xD;
        -  Patients will be recruited from Internal Medicine Department, Tanta University Hospital,&#xD;
           Tanta, Egypt.&#xD;
&#xD;
      This study will be randomized, controlled, parallel, prospective clinical study. Accepted&#xD;
      patients will be randomized into 2 groups as the following&#xD;
&#xD;
        -  Group 1 (Control group): 30 patients will receive maximum tolerated dose of ACEI for six&#xD;
           months&#xD;
&#xD;
        -  Group 2 (Fexofenadine group): 30 patients will receive maximum tolerated dose of ACEI&#xD;
           plus fexofenadine tablets 60 mg once daily for six months&#xD;
&#xD;
      The primary end point will be the change in Urinary albumin to creatinine ratio (UACR) after&#xD;
      six months of treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in urinary albumin creatinine ratio (UACR)</measure>
    <time_frame>After 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary cyclophilin A</measure>
    <time_frame>After 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary monocyte chemoattractant protein-1 (MCP-1)</measure>
    <time_frame>After 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fexofenadine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine Pill</intervention_name>
    <description>fexofenadine tablets 60 mg once daily will be taken for six months</description>
    <arm_group_label>Fexofenadine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>lactose oral tablet</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged â‰¥ 18 years&#xD;
&#xD;
          -  Confirmed diagnosis of Type 2 diabetes mellitus at least 6 months prior to screening&#xD;
&#xD;
          -  Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary&#xD;
             albumin creatinine ratio (UACR) &gt;30mg/g) despite treatment with maximum tolerated dose&#xD;
             of ACE inhibitors for at least 8 weeks prior to the screening&#xD;
&#xD;
          -  Hemoglobin A1c &gt; 6.5 % with regular use of insulin and/or oral glucose lowering agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Severe renal impairment (eGFR&lt; 30 mL/min/1.73 m2 at screening)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Chronic heart failure&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Inflammatory or autoimmune disease&#xD;
&#xD;
          -  History of kidney disease other than diabetic nephropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Basma M El-fatatry, Master</last_name>
    <phone>201094114899</phone>
    <email>basma.mahrous.clinical@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Pharmacy, Tanta University</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Basma Mahrous El-Fatatry</investigator_full_name>
    <investigator_title>Principal investigator, Assistant lecturer of Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

